Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT 1A/5-HT2A/5-HT7 and dopamine D 2/D3 receptors

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 42-50

  Zajdel, Paweł ^a   Marciniec, Krzysztof ^b   Maślankiewicz, Andrzej ^b   Grychowska, Katarzyna ^a   Satała, Grzegorz ^c   Duszyńska, Beata ^c   Lenda, Tomasz ^c   Siwek, Agata ^a   Nowak, Gabriel ^a   Partyka, Anna ^a   Wróbel, Dagmara ^a   Jastrzȩbska Wiȩsek, Magdalena ^a   Bojarski, Andrzej J ^c   Wesołowska, Anna ^a   Pawłowski, MacIej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

2,3 Dichlorophenylpiperazine; 5 HT 2A antagonist; 5 HT7 antagonist; Aripiprazole; D2 partial agonist; Depression; Dopamine; Isoquinoline sulfonamides; Long chain arylpiperazines; Quinoline sulfonamides; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ISOQUINOLINE DERIVATIVE; N [3 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL)PROPYL]QUINOLINE 7 SULFONAMIDE; N [4 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL)BUTYL]ISOQUINOLINE 4 SULFONAMIDE; N [4 (4 (2,3DICHLOROPHENYL)PIPERAZIN 1 YL)BUTYL]ISOQUINOLINE 3 SULFONAMIDE; QUINOLINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOQUINOLINES; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PIPERAZINES; QUINOLINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84871568579     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.11.042     Document Type: Article

References (26)

1. B. Bang-Andersen, T. Ruhland, M. Jørgensen, G. Smith, K. Frederiksen, K.G. Jensen, H. Zhong, S.M. Nielsen, S. Hogg, A. Mørk, and T.B. Stensbøl Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder J. Med. Chem. 54 2011 3206 3221
2. G. Sarkisyan, A.J. Roberts, and P.B. Hedlund The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior Behav. Brain Res. 209 2010 99 108
3. S. Butini, S. Gemme, G. Campiani, S. Franceschini, F. Trotta, M. Boriello, N. Ceres, S. Ros, S.S. Coccone, M. Bernetti, M.D. Angelis, M. Brindisi, V. Nacci, I. Fiorini, E. Novellino, A. Cagnotto, T. Mennini, K. Sandager-Nielsen, J.T. Andreasen, J. Scheel-Kruger, J.D. Mikkelsen, and C. Fattorusso Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior J. Med. Chem. 52 2009 151 169
4. 4-agents: the synthesis and pharmacological evaluation Bioorg. Med. Chem. 20 2012 1545 1556
5. P. Zajdel, K. Marciniec, A. Maślankiewicz, M.H. Paluchowska, G. Satała, A. Partyka, M. Jastrzȩbska-Wiȩsek, D. Wróbel, A. Wesołowska, B. Duszyńska, A.J. Bojarski, and M. Pawłowski Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands Bioorg. Med. Chem. 19 2011 6750 6759
6. K. Marciniec, A. Maślankiewicz, M. Pawłowski, and P. Zajdel From haloquinolines and halopyridines to quinoline- and pyridinesulfonyl chlorides and sulfonamides Heterocycles 71 2007 1975 1990
7. R. MacKenzie, D. VanLeeuwen, T. Pugsley, Y. Shih, S. Demattos, L. Tang, R. Todd, and K. O'Malley Characterization of the human dopamine D3 receptor expressed in transfected cell lines Eur. J. Pharmacol. 266 1994 79 85
8. J.-C. Martel, M.-B. Assié, L. Bardin, R. Depoortère, D. Cussac, and A. Newman-Tancredi 5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception Br. J. Pharmacol. 158 2009 232 242
9. N. Adham, J.M. Zgombick, J. Bard, and T.A. Branchek Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation J. Pharmacol. Exp. Ther. 287 1998 508 514
10. N.A. Darmani, B.R. Martin, U. Pandey, and R.A. Glennon Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav. 36 1990 901 906
11. R.D. Porsolt, A. Bertin, N. Blavet, M. Deniel, and M. Jalfre Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity Eur. J. Pharmacol. 57 1979 201 210
12. A.H. Newman, J. Cao, C.J. Bennett, M.J. Robarge, R.A. Freeman, and R.R. Luedtke N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists Bioorg. Med. Chem. Lett. 13 2003 2179 2183
13. J. Chen, K. Ding, B. Levant, and S. Wang Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility Bioorg. Med. Chem. Lett. 16 2006 443 446
14. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.-X. Liu, D.R. Sibley, B.L. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
15. T. Sumiyoshi, V. Bubenikova-Valesova, J. Horacek, and B. Bert Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics Adv. Ther. 25 2008 1037 1056
16. G.V. Carr, and I. Lucki The role of serotonin receptor subtypes in treating depression: a review of animal studies Psychopharmacology 213 2011 265 287
17. M. Bourin, F. Chenu, C. Prica, and M. Hascoët Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice Psychopharmacology 206 2009 97 107
18. F. Goodwin, E. Whitham, and S. Ghaemi Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are moods stabilizers? CNS Drugs 25 2011 819 827
19. R.K. Owenby, L.T. Brown, and J.N. Brown Use of risperidone as augmentation treatment for major depressive disorder Ann. Pharmacother. 45 2011 95 100
20. A.V. Ravindran, A. Al-Subaie, and G. Abraham Quetiapine: novel uses in the treatment of depressive and anxiety disorders Expert Opin. Investig. Drugs 19 2010 1187 1204
21. M. Carlsson, and A. Carlsson Systems within the basal ganglia: implications for schizophrenia and Parkinson's disease Trends Neurosci. 13 1990 272 276
22. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
23. A.J. Bojarski, M.T. Cegla, S. Charakchieva-Minol, M.J. Mokrosz, M. Mackowiak, S. Misztal, and J.L. Mokrosz Structure-activity relationship studies of CNS agents. Part 9: 5-HT1A and 5-HT2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-beta-carbolines Pharmazie 48 1993 289 294
24. M.H. Paluchowska, R. Bugno, B. Duszyńska, E. Tatarczyńska, A. Nikiforuk, T. Lenda, and E. Chojnacka-Wójcik The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m- trifluoromethylphenyl)piperazines Bioorg. Med. Chem. 15 2007 7116 7125
25. Y. Cheng, and W. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
26. M.J. Owens, W.N. Morgan, S.J. Plott, and C.B. Nemeroff Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites J. Pharmacol. Exp. Ther. 283 1997 1305 1322